Document Type : Original Article
Authors
1
Department of Bacteriology, Mycology and Immunology, Faculty of Veterinary Medicine, Beni-Suef University, Beni Suef 62511, Egypt.
2
Department of Poultry Diseases, Faculty of Veterinary Medicine, Beni-Suef University, Beni Suef 62511, Egypt.
3
Department of Pharmacology, Faculty of Veterinary Medicine, Beni-Suef University, Beni Suef 62511, Egypt.
4
Department of Poultry Breeding, Animal Production Research Institute, Agriculture Research Center, Dokki, Giza 12311, Egypt.
5
Postgraduate at Department of Bacteriology, Mycology and Immunology, Faculty of Veterinary Medicine, Beni-Suef University, Beni Suef 62511, Egypt.
6
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni Suef 62511, Egypt.
7
Department of Materials Science and Nanotechnology, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni Suef 62764, Egypt.
Abstract
Colibacillosis is an infectious disease produced by avian pathogenic E.coli associated with reduced productivity, high mortality and condemnation rates and increased treatment costs. Colistin has become the predominant treatment option against multidrug resistant (MDR) Gram-negative bacteria. Nevertheless, swift progression of renal damage caused by injection of colistin frequently hinders the attainment of ideal therapeutic dosages. The present work aimed to formulate colistin-loaded niosomes (CLN) to improve efficacy and decrease toxicity of colistin as a potential treatment against avian pathogenic E.coli in broiler chicks. The CLN of tween 60, cholesterol and dihexadecyl phosphate in the molar ratio of 1:2:0.1 was chosen as an efficient carrier for delivering colistin. The minimum inhibitory concentration for CLN was approximately 12 times lower than that of free colistin with enhanced pharmacokinetic parameter, demonstrating the higher efficacy of CLN. Efficacy and safety of CLN were investigated in vivo using an experimental bird model using E. coli. In contrast to control positive group, serum albumin, total protein and creatinine concentrations were significantly lower following parenteral CLN administration. Histopathological examination of the kidney demonstrated that CLN inhibits nephrotoxic effects when compared to free colistin. Additionally, microscopical examination of liver, lung, and heart samples demonstrated the safety of the CLN. In contrast to colistin sulphate, niosomal colistin demonstrated superior pharmacological activity and efficacy suggesting that administering parenteral CLN is more effective and safer than conventional colistin.
Keywords
Main Subjects
)
View on SCiNiTO